Clinical Response to Seribantumab, an Anti–Human Epidermal Growth Factor Receptor-3 Immunoglobulin 2 Monoclonal Antibody, in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma Harboring an <i>NRG1</i> FusionSubotheni Thavaneswaran, David M. Thomas, Wei Yen Chan et al.|JCO Precision Oncology|2022Cited by 8
Multigene panel next generation sequencing in metastatic colorectal cancer in an Australian populationUdit Nindra, Wei Chua, Abhijit Pal et al.|PLoS ONE|2023Cited by 6
Real‐world tolerance and outcomes of oxaliplatin‐based adjuvant chemotherapy for stage III colon cancer—Does dose intensity matter?Robert Yoon, Weng Ng, Kate Wilkinson et al.|Asia-Pacific Journal of Clinical Oncology|2023Cited by 4
Rectal cancer treatment and outcomes in elderly patients treated with curative intent.Sharlyn Kang, Stephanie Lim, Sarah Maloney et al.|Journal of Clinical Oncology|2019Cited by 2
Patterns of adjuvant therapy use and survival outcomes in patients with rectal cancer not receiving neoadjuvant therapy in an Australian cohort.Kate Wilkinson, Daniel Brungs, Sharlyn Kang et al.|Journal of Clinical Oncology|2019Cited by 0